# Paxil CR Bioequivalence Study Brazil

> **NCT01316926** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Depressive Disorder

## Interventions

- **DRUG:** Test formulation
- **DRUG:** Reference formulation

## Key facts

- **NCT ID:** NCT01316926
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-09
- **Primary completion:** 2009-10-05
- **Final completion:** 2009-10-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316926, "Paxil CR Bioequivalence Study Brazil". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01316926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*